Schroder Investment Management Group increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 281.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 66,856 shares of the company’s stock after acquiring an additional 49,310 shares during the period. Schroder Investment Management Group owned approximately 0.08% of IDEXX Laboratories worth $10,733,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the stock. Old Mutual Global Investors UK Ltd. bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $83,723,000. Sheaff Brock Investment Advisors LLC increased its holdings in IDEXX Laboratories by 4.2% during the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 6,076 shares of the company’s stock worth $981,000 after acquiring an additional 243 shares during the period. WMS Partners LLC increased its holdings in IDEXX Laboratories by 0.3% during the 2nd quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock worth $256,000 after acquiring an additional 4 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its holdings in IDEXX Laboratories by 6,536.8% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 165,853 shares of the company’s stock worth $26,772,000 after acquiring an additional 163,354 shares during the period. Finally, Calamos Advisors LLC increased its holdings in IDEXX Laboratories by 2.8% during the 2nd quarter. Calamos Advisors LLC now owns 22,763 shares of the company’s stock worth $3,674,000 after acquiring an additional 615 shares during the period. 87.73% of the stock is currently owned by institutional investors and hedge funds.
IDXX has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, June 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a report on Tuesday, June 13th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a report on Monday, August 21st. Finally, BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $174.00.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at 158.97 on Friday. The company’s 50-day moving average is $155.18 and its 200-day moving average is $158.87. The company has a market cap of $13.87 billion, a price-to-earnings ratio of 54.69 and a beta of 0.49. IDEXX Laboratories, Inc. has a 12-month low of $102.45 and a 12-month high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business had revenue of $508.90 million for the quarter, compared to the consensus estimate of $502.44 million. During the same quarter in the previous year, the firm earned $0.74 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. Equities research analysts predict that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current year.
In related news, Director Lawrence D. Kingsley bought 2,000 shares of the stock in a transaction dated Thursday, August 3rd. The shares were purchased at an average price of $151.76 per share, with a total value of $303,520.00. Following the completion of the acquisition, the director now owns 3,344 shares of the company’s stock, valued at $507,485.44. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Chairman Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $155.22, for a total transaction of $2,793,960.00. The disclosure for this sale can be found here. Insiders sold 151,734 shares of company stock worth $23,436,626 in the last three months. Insiders own 2.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Schroder Investment Management Group Has $10.73 Million Position in IDEXX Laboratories, Inc. (IDXX)” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/16/schroder-investment-management-group-has-10-73-million-position-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.